<DOC>
	<DOCNO>NCT01396200</DOCNO>
	<brief_summary>The purpose study determine feasibility give ( ) rapamycin ( ii ) hydroxychloroquine ( HCQ ) , standard dose infusional cyclophosphamide pulse dexamethasone ( cy/dex ) patient relapsed/refractory multiple myeloma , well feasibility obtain multiple blood bone marrow sample treatment assess pharmacodynamic effect treatment .</brief_summary>
	<brief_title>Cyclophosphamide Pulse Dexamethasone With Rapamycin Hydroxychloroquine</brief_title>
	<detailed_description>Multiple myeloma plasma cell neoplasm median survival 3 5 year . Recent advance improve patient outlook , disease remain incurable patient become refractory treatment , develop organ dysfunction myeloma , encounter severe toxicity therapy , limit treatment option . Subjects age 18 relapse refractory multiple myeloma least one prior therapy , life expectancy least 4 week ECOG performance status 0,1 2 include . The investigator propose initial pilot trial test feasibility give standard chemotherapy infusional cyclophosphamide pulse dexamethasone ( cy/dex ) four day , together investigational agent , oral rapamycin ( cohort A ) , separate parallel arm , oral hydroxychloroquine ( HCQ ) ( cohort B ) . The investigator enroll 3 patient cohort A 3 patient cohort B , plan 1st dose level overall phase I/II trial succeed trial feasibility demonstrate . The 6 patient pilot trial include total number patient overall study complete funding secure . Feasibility define ability deliver regimen plan ability perform plan correlative study . Subjects receive 12 cycle follow 12 month last cycle . Data collect include toxicity , response rate , correlative study examine pharmacodynamics mTOR inhibition autophagy pharmacokinetics rapamycin HCQ .</detailed_description>
	<mesh_term>Dexamethasone acetate</mesh_term>
	<mesh_term>Dexamethasone</mesh_term>
	<mesh_term>Dexamethasone 21-phosphate</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<mesh_term>Everolimus</mesh_term>
	<mesh_term>BB 1101</mesh_term>
	<mesh_term>Hydroxychloroquine</mesh_term>
	<criteria>Each subject must meet ALL follow criterion screen enrol : Histologically confirm multiple myeloma Documented relapse persistent disease least one prior therapy ( may include autologous allogeneic bone marrow transplantation ) Need therapy myeloma , determine patient treat physician Age 18 year ECOG PS 02 History allergic reaction compound similar chemical biological composition rapamycin hydroxychloroquine Patients may take follow medication study ( rapamycin arm ) , consider eligible medication discontinue 72 hr prior first dose Rapamycin : Carbamazepine ( e.g . Tegretol ) Rifabutin ( e.g . Mycobutin ) Rifampin ( e.g . Rifadin ) Rifapentine ( e.g . Priftin ) St. Johns Wort Clarithromycin ( e.g . Biaxin ) Cyclosporin e.g . ( Neorla Sandimmune ) Diltiazem ( e.g . Cardizem ) Erythromycin ( e.g . AkneMycin , EryTab ) Itraconazole ( e.g . Sporonox ) Fluconazole ( e.g . Diflucan ) Ketoconazole ( e.g . Nizoral ) Telithromycin ( e.g . Ketek ) Verapamil ( e.g . Calan SR , Isoptin , Verelan ) Voriconazole ( e.g . VFEND ) Tacrolimus ( e.g . Prograf ) Known macular degeneration retinopathy ( diabetic otherwise ) , porphyria , psoriasis ( wellcontrolled psoriasis allow provide care specialist agree monitor patient exacerbation ) Patients follow cytopenia : ANC 1.0 x 109/L ; Platelets 50 x 109/L Serum Creatinine 2.5 mg/dL ; Total Direct Bilirubin 2.0 mg/dL ; Fasting Glucose 200mg/dL Other condition would require therapy hydroxychloroquine , include limited , follow : Systemic lupus Rheumatoid arthritis Porphyria cutanea tarda Malaria treatment prophylaxis Other active malignancy , except : Basal cell squamous cell carcinoma skin Treated carcinoma situ Localized prostate adenocarcinoma ( stage T1a T1b ) stable PSA period least 4 month allow Patients prior malignancy treat chemotherapy , biologic agent , and/or radiation eligible study complete therapy 4 year previously evidence recurrent disease Patients prior malignancy treat surgery alone eligible study complete therapy 2 year previously evidence recurrent disease Uncontrolled intercurrent illness include , limited , follow : Uncontrolled ongoing infection Symptomatic congestive heart failure Unstable angina pectoris Uncontrolled cardiac arrhythmia Psychiatric illness social situation would limit compliance study requirement Inability understand unwillingness sign inform consent document Concurrent antimyeloma therapy within : 7 day prior corticosteroid 14 day prior antimyeloma agent , include thalidomide lenalidomide 28 day different investigational regimen 14 day radiation Women childbearing unwilling unable use acceptable method avoid pregnancy entire study period 30 day last dose study drug . Women pregnant breastfeeding</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2013</verification_date>
</DOC>